TBOPP |
Catalog No.GC38855 |
TBOPP es un inhibidor selectivo de DOCK1 con una IC50 de 8,4 μM. TBOPP se une al dominio DOCK1 DHR-2 con alta afinidad (Kd de 7,1 μM), tiene actividad antitumoral para tipos de tumores mÁs amplios.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1996629-79-8
Sample solution is provided at 25 µL, 10mM.
TBOPP is a selective inhibitor of DOCK1 with an IC50 of 8.4 μM. TBOPP binds to the DOCK1 DHR-2 domain with high affinity (Kd of 7.1 μM), has anti-tumor activity for broader types of tumors[1].
TBOPP (12.5 µM; 3 days; 3LL cells) treatment inhibits DOCK1-mediated invasion, macropinocytosis, and survival under the condition of glutamine deprivation without impairing the biological functions of the closely related DOCK2 and DOCK5 proteins[1]. Cell Viability Assay[1] Cell Line: 3LL cells
TBOPP (0.67 mg per mouse; administrated on days 0, 1, 3, and 5; for 2 weeks; C57BL/6 mice) treatment effectively suppresses metastasis of cancer cells in vivo and the number of lymphocytes in the spleen is not changed, the body weight is also unchanged between TBOPP-treated and non-treated mice[1]. Animal Model: C57BL/6 mice (6- to 8-week-old) with ex-3LL cells[1]
[1]. Tajiri H, et al. Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1. Cell Rep. 2017 May 2;19(5):969-980.
Average Rating: 5
(Based on Reviews and 4 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *